JP2022514214A5 - - Google Patents
Info
- Publication number
- JP2022514214A5 JP2022514214A5 JP2021531946A JP2021531946A JP2022514214A5 JP 2022514214 A5 JP2022514214 A5 JP 2022514214A5 JP 2021531946 A JP2021531946 A JP 2021531946A JP 2021531946 A JP2021531946 A JP 2021531946A JP 2022514214 A5 JP2022514214 A5 JP 2022514214A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- alkylene
- alkyl
- lnp composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024146107A JP2024167309A (ja) | 2018-12-05 | 2024-08-28 | 修飾されたアミン脂質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775783P | 2018-12-05 | 2018-12-05 | |
| US62/775,783 | 2018-12-05 | ||
| PCT/US2019/064663 WO2020118041A1 (en) | 2018-12-05 | 2019-12-05 | Modified amine lipids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146107A Division JP2024167309A (ja) | 2018-12-05 | 2024-08-28 | 修飾されたアミン脂質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514214A JP2022514214A (ja) | 2022-02-10 |
| JP2022514214A5 true JP2022514214A5 (https=) | 2023-02-13 |
| JP7547335B2 JP7547335B2 (ja) | 2024-09-09 |
Family
ID=69006051
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531946A Active JP7547335B2 (ja) | 2018-12-05 | 2019-12-05 | 修飾されたアミン脂質 |
| JP2024146107A Pending JP2024167309A (ja) | 2018-12-05 | 2024-08-28 | 修飾されたアミン脂質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146107A Pending JP2024167309A (ja) | 2018-12-05 | 2024-08-28 | 修飾されたアミン脂質 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12077483B2 (https=) |
| EP (1) | EP3891127A1 (https=) |
| JP (2) | JP7547335B2 (https=) |
| KR (1) | KR20210108969A (https=) |
| CN (2) | CN113260607A (https=) |
| AU (1) | AU2019392673A1 (https=) |
| BR (1) | BR112021010853A2 (https=) |
| CA (1) | CA3121621A1 (https=) |
| CO (1) | CO2021008838A2 (https=) |
| EA (1) | EA202191559A1 (https=) |
| IL (2) | IL283622B2 (https=) |
| MA (1) | MA54385A (https=) |
| MX (1) | MX2021006150A (https=) |
| PH (1) | PH12021551279A1 (https=) |
| SA (1) | SA521422179B1 (https=) |
| SG (1) | SG11202105367QA (https=) |
| TW (2) | TW202504886A (https=) |
| UA (1) | UA129215C2 (https=) |
| WO (1) | WO2020118041A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021010853A2 (pt) | 2018-12-05 | 2021-08-31 | Intellia Therapeutics, Inc. | Lipídios de amina modificados |
| CN114127044A (zh) * | 2019-04-25 | 2022-03-01 | 英特利亚治疗股份有限公司 | 可电离的胺类脂质和脂质纳米颗粒 |
| CA3145913A1 (en) | 2019-07-29 | 2021-02-04 | James Everett Dahlman | Nanomaterials containing constrained lipids and uses thereof |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| IL294318A (en) | 2020-01-09 | 2022-08-01 | Guide Therapeutics Llc | Nanomaterials |
| CA3181340A1 (en) | 2020-04-28 | 2021-11-04 | Intellia Therapeutics, Inc. | Methods of in vitro cell delivery |
| EP4228658A4 (en) | 2020-10-14 | 2025-02-19 | George Mason Research Foundation, Inc. | IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF |
| IL303506A (en) | 2020-12-11 | 2023-08-01 | Intellia Therapeutics Inc | Polynucleotides, compositions, and methods for genome editing involving deamination |
| EP4281080A4 (en) | 2021-01-20 | 2025-09-24 | Beam Therapeutics Inc | NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT |
| CN116761888A (zh) * | 2021-01-20 | 2023-09-15 | 比姆医疗股份有限公司 | 纳米材料 |
| US20240180954A1 (en) | 2021-02-04 | 2024-06-06 | Shionogi & Co., Ltd. | Cationic lipid |
| IL307740A (en) | 2021-04-17 | 2023-12-01 | Intellia Therapeutics Inc | DNA-dependent protein kinase inhibitors and their compositions and uses |
| WO2022261292A1 (en) | 2021-06-10 | 2022-12-15 | Intellia Therapeutics, Inc. | Modified guide rnas comprising an internal linker for gene editing |
| US20250295755A1 (en) | 2021-10-22 | 2025-09-25 | Sail Biomedicines, Inc. | Mrna vaccine composition |
| CA3237303A1 (en) | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing |
| CA3238764A1 (en) | 2021-11-23 | 2023-06-01 | Siddharth Patel | A bacteria-derived lipid composition and use thereof |
| EP4452239A1 (en) | 2021-12-20 | 2024-10-30 | Sail Biomedicines, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
| CN114874150A (zh) * | 2022-02-22 | 2022-08-09 | 中国科学院基础医学与肿瘤研究所(筹) | 一种双价可电离脂质化合物、组合物及其应用 |
| CN114213347B (zh) * | 2022-02-22 | 2022-05-20 | 中国科学院基础医学与肿瘤研究所(筹) | 一种双价可电离脂质化合物、组合物及其应用 |
| CN116354836A (zh) * | 2022-03-25 | 2023-06-30 | 深圳市新合生物医疗科技有限公司 | 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统 |
| CN119384498A (zh) | 2022-06-16 | 2025-01-28 | 因特利亚治疗公司 | 用于对细胞进行遗传修饰的方法和组合物 |
| CA3260437A1 (en) * | 2022-07-20 | 2024-01-25 | Beam Therapeutics Inc. | NANOMATERIALS INCLUDING TRIOLS |
| WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
| EP4638783A2 (en) | 2022-12-22 | 2025-10-29 | Intellia Therapeutics, Inc. | Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies |
| CN120418427A (zh) | 2022-12-23 | 2025-08-01 | 因特利亚治疗公司 | 用于基因组编辑的系统和方法 |
| CN121057577A (zh) | 2023-01-27 | 2025-12-02 | 赛欧生物医药股份有限公司 | 经修饰的脂质组合物及其用途 |
| WO2024220752A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Rna therapeutic compositions |
| WO2024220712A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Vaccine compositions |
| WO2024220625A1 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids |
| AU2024279964A1 (en) * | 2023-05-30 | 2025-11-13 | Liberate Bio, Inc. | Lipid compounds, compositions, and uses thereof |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| EP4725938A1 (en) * | 2023-06-07 | 2026-04-15 | InnoVec Biotherapeutics | Ionizable lipid compound, lipid carrier comprising same and use thereof |
| AU2024325364A1 (en) * | 2023-08-16 | 2026-03-26 | Beam Therapeutics Inc. | Ionizable lipids with branched head groups |
| WO2025049481A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025064396A1 (en) | 2023-09-18 | 2025-03-27 | Intellia Therapeutics, Inc. | Nuclease resistant double stranded dna product for non-viral delivery to a cell and methods of production thereof |
| WO2025064401A1 (en) | 2023-09-18 | 2025-03-27 | Intellia Therapeutics, Inc. | Nuclease resistant single stranded dna product for non-viral delivery to a cell and methods of production thereof |
| WO2025106930A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| WO2025159966A1 (en) * | 2024-01-23 | 2025-07-31 | Beam Therapeutics Inc. | Compositions and methods for altering a nucleobase in a transthyretin polynucleotide |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025193861A2 (en) * | 2024-03-12 | 2025-09-18 | Tessera Therapeutics, Inc. | Lipid nanoparticles for delivery of therapeutic payloads to cells |
| WO2025240946A1 (en) | 2024-05-17 | 2025-11-20 | Intellia Therapeutics, Inc. | Lipid nanoparticles and lipid nanoparticle compositions |
| WO2026006579A1 (en) * | 2024-06-27 | 2026-01-02 | Innovac Therapeutics Hk Limited | Ether-containing novel ionizable lipids and their uses thereof |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026035680A1 (en) | 2024-08-06 | 2026-02-12 | Kernal Biologics, Inc. | Compositions and methods for delivery of agents |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
| US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| KR20190039347A (ko) * | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| ES2795110T3 (es) * | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| EP3031921B1 (en) * | 2012-12-12 | 2025-03-12 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| CN107879960B (zh) | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
| US10426737B2 (en) * | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| RU2571176C1 (ru) * | 2014-07-14 | 2015-12-20 | Гиа Маргович Гвичия | Светодиодная матрица |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| US10125092B2 (en) | 2014-09-05 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| JP6531983B2 (ja) * | 2015-07-31 | 2019-06-19 | パナソニックＩｐマネジメント株式会社 | 自動運転装置、自動運転支援方法及び自動運転支援プログラム |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| LT3436077T (lt) * | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| AU2017356699B2 (en) * | 2016-11-08 | 2021-11-11 | Ramot At Tel-Aviv University Ltd. | Cationic lipids for nucleic acid delivery and preparation thereof |
| BR112021010853A2 (pt) * | 2018-12-05 | 2021-08-31 | Intellia Therapeutics, Inc. | Lipídios de amina modificados |
-
2019
- 2019-12-05 BR BR112021010853-0A patent/BR112021010853A2/pt unknown
- 2019-12-05 UA UAA202103727A patent/UA129215C2/uk unknown
- 2019-12-05 MX MX2021006150A patent/MX2021006150A/es unknown
- 2019-12-05 TW TW113114385A patent/TW202504886A/zh unknown
- 2019-12-05 MA MA054385A patent/MA54385A/fr unknown
- 2019-12-05 CA CA3121621A patent/CA3121621A1/en active Pending
- 2019-12-05 WO PCT/US2019/064663 patent/WO2020118041A1/en not_active Ceased
- 2019-12-05 EA EA202191559A patent/EA202191559A1/ru unknown
- 2019-12-05 CN CN201980086265.9A patent/CN113260607A/zh active Pending
- 2019-12-05 CN CN202410977955.6A patent/CN119285480A/zh active Pending
- 2019-12-05 US US17/299,925 patent/US12077483B2/en active Active
- 2019-12-05 SG SG11202105367QA patent/SG11202105367QA/en unknown
- 2019-12-05 KR KR1020217020770A patent/KR20210108969A/ko not_active Ceased
- 2019-12-05 IL IL283622A patent/IL283622B2/en unknown
- 2019-12-05 JP JP2021531946A patent/JP7547335B2/ja active Active
- 2019-12-05 TW TW108144579A patent/TWI841639B/zh active
- 2019-12-05 EP EP19828120.6A patent/EP3891127A1/en active Pending
- 2019-12-05 AU AU2019392673A patent/AU2019392673A1/en not_active Abandoned
- 2019-12-05 IL IL314386A patent/IL314386A/en unknown
-
2021
- 2021-06-01 PH PH12021551279A patent/PH12021551279A1/en unknown
- 2021-06-03 SA SA521422179A patent/SA521422179B1/ar unknown
- 2021-07-02 CO CONC2021/0008838A patent/CO2021008838A2/es unknown
-
2024
- 2024-08-06 US US18/796,047 patent/US20250074866A1/en active Pending
- 2024-08-28 JP JP2024146107A patent/JP2024167309A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514214A5 (https=) | ||
| JP2022530043A5 (https=) | ||
| JP2022501412A5 (https=) | ||
| ES2320181T3 (es) | Composiciones farmaceuticas que tienen un efecto reductor del colesterol. | |
| JP2022530018A5 (https=) | ||
| JP2021511312A5 (https=) | ||
| JP2022536495A5 (https=) | ||
| RS58077B1 (sr) | Trialkil katjonski lipidi i postupci njihove primene | |
| RU99110944A (ru) | Тиенопиримидины с ингибирующим действием по отношению к фосфодиэстеразе v (pde v) | |
| ES2437346T3 (es) | Procedimiento para la producción de derivado de diamina | |
| HUE025782T2 (en) | 5-Aza-cytosine-containing oligonucleotide analogs | |
| JP2025500824A5 (https=) | ||
| JP2025509698A5 (https=) | ||
| DOP2003000678A (es) | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz | |
| EP0739202B1 (en) | Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase | |
| CA3047326A1 (en) | Methods for ameliorating infusion reactions | |
| JP2007505044A5 (https=) | ||
| EA200401519A1 (ru) | N- ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы b | |
| BR112018013928A2 (en) | therapeutic compositions and methods for treating hepatitis b | |
| RU2008119465A (ru) | Производные циклопропилуксусной кислоты и их применение | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| JP7466609B2 (ja) | 析出抑制剤 | |
| US10336777B2 (en) | Cysteine-modifying substrate analogue inhibitors of ribose 5-phosphate isomerase for parasitic diseases, along with methods of their formation and use | |
| RU2007132179A (ru) | Ингибирующие вич производные 2-(4-цианофениламино)пиримидина | |
| US10415040B2 (en) | Nucleic acid amphiphiles and nanostructures |